Treatments with Cord Blood

Our hope is that no family ever needs a stem cell therapy to treat a life-threatening disease. Unfortunately, the reality is that many of us will experience one or more of these conditions in our, or our family’s lifetime. Research has projected that as many as 1 in 217 people could use a cord blood cell therapy in their lifetime1, and with the amazing progress researchers are making on conditions such as autism, Alzheimers’ disease, heart disease and diabetes, this number could substantially change in the foreseeable future. The graphic below shows all the potential diseases that are currently being researched, or are in active clinical trials, using cord blood or cord tissue treatments.

Cord Blood Treatments

Below is a full list of the 80+ diseases that are currently treatable with cord blood.


  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Burkitt’s lymphoma
  • Chronic myeloid leukemia (CML)
  • Juvenile myelomonocytic leukemia (JMML)
  • Non-Hodgkin’s lymphoma Hodgkin’s lymphoma
  • Lymphomatoid granulomatosis
  • Myelodysplastic syndrome (MDS)
  • Chronic myelomonocytic leukemia (CMML)

Bone Marrow Failure Syndromes

  • Amegakaryocytic thrombocytopenia
  • Autoimmune neutropenia (severe)
  • Congenital dyserythropoietic anemia
  • Cyclic neutropenia
  • Diamond-Blackfan anemia
  • Evan’s syndrome
  • Fanconi anemia
  • Glanzmann’s disease
  • Juvenile dermatomyositis
  • Kostmann’s syndrome
  • Red cell aplasia
  • Shwachman syndrome
  • Severe aplastic anemia
  • Congenital sideroblastic anemia
  • Thrombocytopenia with absent radius (TAR syndrome)
  • Dyskeratosis congenita

Blood Disorders

  • Sickle-cell anemia (hemoglobin SS)
  • HbSC disease
  • Sickle βo Thalassemia
  • α-thalassemia major (hydrops fetalis)
  • β-thalassemia major (Cooley’s anemia)
  • β-thalassemia intermedia
  • E-βo thalassemia
  • E-β+ thalassemia

Metabolic Disorders

  • Adrenoleukodystrophy Gaucher’s disease (infantile)
  • Metachromatic leukodystrophy
  • Krabbe disease (globoid cell leukodystrophy)
  • Gunther disease
  • Hermansky-Pudlak syndrome
  • Hurler syndrome
  • Hurler-Scheie syndrome
  • Hunter syndrome
  • Sanfilippo syndrome
  • Maroteaux-Lamy syndrome
  • Mucolipidosis Type II, III
  • Alpha mannosidosis
  • Niemann Pick Syndrome, type A and B
  • Sandhoff Syndrome
  • Tay-Sachs Disease
  • Batten disease (inherited neuronal ceroid lipofuscinosis)
  • Lesch-Nyhan disease


  • Ataxia telangiectasia
  • Chronic granulomatous disease
  • DiGeorge syndrome
  • IKK gamma deficiency
  • Immune dysregulation polyendocrineopathy
  • X-linked Mucolipidosis, Type II
  • Myelokathexis X-linked immunodeficiency
  • Severe combined immunodeficiency
  • Adenosine deaminase deficiency
  • Wiskott-Aldrich syndrome
  • X-linked agammaglobulinemia
  • X-linked lymphoproliferative disease
  • Omenn’s syndrome
  • Reticular dysplasia
  • Thymic dysplasia
  • Leukocyte adhesion deficiency


  • Osteopetrosis
  • Langerhans cell histiocytosis
  • Hemophagocytic lymphohistiocytsis

1 Nietfeld JJ, Pasquini MC, Logan BR, et al. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.